There are 2137 resources available
1249P - PD-L1 expression and survival in stage III unresectable non-small cell lung cancer patients in Denmark
Presenter: Deirdre Cronin-Fenton
Session: E-Poster Display
Resources:
Abstract
1250P - A holistic perspective on plasma proteome changes associated with response to anti-PD-1 treatment in NSCLC patients
Presenter: Emanuela Romano
Session: E-Poster Display
Resources:
Abstract
1251P - Exploring quantitative biomarkers from different tumour volumes for radiomics in lung cancer
Presenter: Sara Ramella
Session: E-Poster Display
Resources:
Abstract
1252P - Construction of immune-related and prognostic lncRNA clusters and identification of their immune and genomic alterations characteristics in lung adenocarcinoma samples
Presenter: Jia Li
Session: E-Poster Display
Resources:
Abstract
1253P - Clinical relevance of immune factors beyond CD8+T cells and mutation status of EGFR and ALK in patients with non-small cell lung cancer
Presenter: Kun Wang
Session: E-Poster Display
Resources:
Abstract
1254P - Radical radiotherapy (RT) and chemoradiotherapy (CRT) in non-small cell lung cancer (NSCLC): Outcomes from a regional cancer network
Presenter: Mohammed Abdul-Latif
Session: E-Poster Display
Resources:
Abstract
1255TiP - CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)
Presenter: Dirk De Ruysscher
Session: E-Poster Display
Resources:
Abstract
1256TiP - Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012
Presenter: Salma Jabbour
Session: E-Poster Display
Resources:
Abstract
1262P - Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033
Presenter: Caicun Zhou
Session: E-Poster Display
Resources:
Abstract
1263P - Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
Presenter: Shun Lu
Session: E-Poster Display
Resources:
Abstract